Advertisement

AAPS PharmSciTech

, Volume 12, Issue 1, pp 165–171 | Cite as

In VitroIn Vivo Correlation for Gliclazide Immediate-Release Tablets Based on Mechanistic Absorption Simulation

  • Sandra Grbic
  • Jelena Parojcic
  • Svetlana Ibric
  • Zorica Djuric
Research Article

Abstract

The aim of this study was to develop a drug-specific absorption model for gliclazide (GLK) using mechanistic gastrointestinal simulation technology (GIST) implemented in GastroPlusTM software package. A range of experimentally determined, in silico predicted or literature data were used as input parameters. Experimentally determined pH-solubility profile was used for all simulations. The human jejunum effective permeability (P eff) value was estimated on the basis of in vitro measured Caco-2 permeability (literature data). The required PK inputs were taken from the literature. The results of the simulations were compared with actual clinical data and revealed that the GIST-model gave accurate prediction of gliclazide oral absorption. The generated absorption model provided the target in vivo dissolution profile for in vitro–in vivo correlation and identification of biorelevant dissolution specification for GLK immediate-release (IR) tablets. A set of virtual in vitro data was used for correlation purposes. The obtained results suggest that dissolution specification of more than 85% GLK dissolved in 60 min may be considered as “biorelevant” dissolution acceptance criteria for GLK IR tablets.

Key words

biorelevant dissolution specification gliclazide in vitro–in vivo correlation (IVIVC) mechanistic absorption simulation 

Notes

Acknowledgments

This work was done under the project Biopharmaceutical Characterization of the Selected BCS Class II and III Drugs: In Vitro and In Silico Methods Evaluation (TR-23015) supported by the Ministry of Science and Technological Development, Republic of Serbia.

References

  1. 1.
    Delrat P, Paraire M, Jochemsen R. Complete bioavailability and lack of food-effect on pharmacokinetics of gliclazide 30 mg modified release in healthy volunteers. Biopharm Drug Dispos. 2002;23:151–7. doi: 10.1002/bdd.303.PubMedCrossRefGoogle Scholar
  2. 2.
    Najib N, Idkaidek N, Beshtawi M, Bader M, Admour I, Mahmood Alam S, et al. Bioequivalence evaluation of two brands of gliclazide 80 mg tablets (Glyzide® & Diamicron®)—in healthy human volunteers. Biopharm Drug Dispos. 2002;23:197–202. doi: 10.1002/bdd.310.PubMedCrossRefGoogle Scholar
  3. 3.
    Hong SS, Lee SH, Lee YJ, Chung SJ, Lee MH, Shim CK. Accelerated oral absorption of gliclazide in human subjects from a soft gelatin capsule containing a PEG 400 suspension of gliclazide. J Control Release. 1998;51:185–92. doi: 10.1016/S0168-3659(97)00167-3.PubMedCrossRefGoogle Scholar
  4. 4.
    Özkan Y, Atay T, Dikmen N, Işimer A, Aboul-Enein HY. Improvement of water solubility and in vitro dissolution rate of gliclazide by complexation with β-cyclodextrin. Pharm Acta Helv. 2000;74:365–70. doi: 10.1016/S0031-6865(99)00063-1.PubMedCrossRefGoogle Scholar
  5. 5.
    Shewale BD, Fursule RA, Sapkal NP. Effect of pH and hydroxylpropyl-β-cyclodextrin on solubility and stability of gliclazide. Int J Health Res. 2008;1:95–9.Google Scholar
  6. 6.
    Kobayashi K, Kimura M, Sakoguchi T, Kitani Y, Hata M, Matsuoka A. Influence of blood proteins on biomedical analysis. III. Pharmacokinetics and protein binding of gliclazide. J Pharm Dyn. 1981;4:436–42.Google Scholar
  7. 7.
    Davis TME, Daly F, Walsh JP, Ilett KF, Beilby JP, Dusci LJ, et al. Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes. Br J Clin Pharmacol. 2000;49:223–30. doi: 10.1046/j.1365-2125.2000.00162.x.PubMedCrossRefGoogle Scholar
  8. 8.
    Rana MKZ. Gliclazide and glibenclamide interactions with antacids and H2-antagonists. Ph.D Thesis, Department of Chemistry, University of Karachi, Pakistan. 2003. http://prr.hec.gov.pk/Chapters/973-1.pdf. Accessed 23 Jun 2010.
  9. 9.
    Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413–20. doi: 10.1023/A:1016212804288.PubMedCrossRefGoogle Scholar
  10. 10.
    Yu LX, Lipka E, Crison JR, Amidon G. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv Drug Deliv Rev. 1996;19:359–76. doi: 10.1016/0169-409X(96)00009-9.PubMedCrossRefGoogle Scholar
  11. 11.
    Norris DA, Leesman GD, Sinko PJ, Grass GM. Development of predictive pharmacokinetic simulation models for drug discovery. J Control Release. 2000;65:55–62. doi: 10.1016/S0168-3659(99)00232-1.PubMedCrossRefGoogle Scholar
  12. 12.
    Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev. 2001;50 Suppl 1:S41–67. doi: 10.1016/S0169-409X(01)00179-X.PubMedCrossRefGoogle Scholar
  13. 13.
    Yokoe J, Iwasaki N, Haruta S, Kadono K, Ogawara K, Higaki K, et al. Analysis and prediction of absorption behavior of colon-targeted prodrug in rats by GI-transit-absorption model. J Control Release. 2003;86:305–13. doi: 10.1016/S0168-3659(02)00424-8.PubMedCrossRefGoogle Scholar
  14. 14.
    Okumu A, DiMaso M, Löbenberg R. Computer simulations using GastroPlusTM to justify a biowaiver for etoricoxib solid oral drug products. Eur J Pharm Biopharm. 2009;72:91–8. doi: 10.1016/j.ejpb.2008.10.019.PubMedCrossRefGoogle Scholar
  15. 15.
    Food and Drug Administration/Center for Drug Evaluation and Research. Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. 2000. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070246.pdf. Accessed 23 Jun 2010.
  16. 16.
    Głowka FK, Hermann TW, Zabel M. Bioavailability of gliclazide from some formulation tablets. Int J Pharm. 1998;172:71–7. doi: 10.1016/S0378-5173(98)00167-7.CrossRefGoogle Scholar
  17. 17.
    Al-Salami H, Butt G, Tucker I, Fawcett P, Golocorbin-Kon S, Mikov I, et al. Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats. Eur J Drug Metabol Pharmacokinet. 2009;34:43–50.CrossRefGoogle Scholar
  18. 18.
    Al-Salami H, Butt G, Tucker I, Mikov M. Influence of the semisynthetic bile acid (MKC) on the ileal permeation of gliclazide in healthy and diabetic rats. Pharmacol Rep. 2008;60:532–41.PubMedGoogle Scholar
  19. 19.
    Wu CY, Benet L. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22:11–23. doi: 10.1007/s11095-004-9004-4.PubMedCrossRefGoogle Scholar
  20. 20.
    Benet L, Amidon G, Barends D, Lennernäs H, Polli J, Shah V, et al. The use of BDDCS in classifying the permeability of marketed drugs. Pharm Res. 2007;52:483–8. doi: 10.1007/s11095-007-9523-x.Google Scholar
  21. 21.
    European Medicines Agency, Committee For Medicinal Products For Human Use (CHMP), Guideline On The Investigation Of Bioequivalence. 2010. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf. Accessed 5 Nov 2010
  22. 22.
    Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations. 1997. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070239.pdf. Accessed 26 Oct 2010
  23. 23.
    Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, et al. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res. 2002;19:921–5. doi: 10.1023/A:1016473601633.PubMedCrossRefGoogle Scholar
  24. 24.
    Stetinova V, Polaskova A, Smetanova L, Kholova D, Herout V, Kvetina J. Toxicological studies, membrane transport and pharmacodynamic effect of gliclazide in rats. Toxicol Lett. 2008;180 Suppl 1:S58–9. doi: 10.1016/j.toxlet.2008.06.639.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2010

Authors and Affiliations

  • Sandra Grbic
    • 1
  • Jelena Parojcic
    • 1
  • Svetlana Ibric
    • 1
  • Zorica Djuric
    • 1
  1. 1.Department of Pharmaceutical Technology and CosmetologyFaculty of Pharmacy, University of BelgradeBelgradeSerbia

Personalised recommendations